133 related articles for article (PubMed ID: 8669868)
1. Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; de e Nictolis M; Garbisa S; Masiero L; Romanini C; Graziella B
Anticancer Res; 1995; 15(6B):2799-804. PubMed ID: 8669868
[TBL] [Abstract][Full Text] [Related]
2. Increased serum 72 KDa metalloproteinase in serous ovarian tumors: comparison with CA 125.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; Romanini C; Biagini G
Anticancer Res; 1996; 16(4A):2123-7. PubMed ID: 8712754
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression.
Torng PL; Mao TL; Chan WY; Huang SC; Lin CT
Gynecol Oncol; 2004 Feb; 92(2):559-67. PubMed ID: 14766248
[TBL] [Abstract][Full Text] [Related]
4. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
[TBL] [Abstract][Full Text] [Related]
5. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.
Lengyel E; Schmalfeldt B; Konik E; Späthe K; Härting K; Fenn A; Berger U; Fridman R; Schmitt M; Prechtel D; Kuhn W
Gynecol Oncol; 2001 Aug; 82(2):291-8. PubMed ID: 11531282
[TBL] [Abstract][Full Text] [Related]
6. [Construction and utilization of the prognostic model of serous ovarian adenocarcinoma].
Yang R; Feng J; Fang XZ; Bai F; Cheng YX; Liu C; Zhu W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2006 Jul; 41(7):459-63. PubMed ID: 17083811
[TBL] [Abstract][Full Text] [Related]
7. Recurrence patterns in locally advanced cervical carcinoma: role of nodal status and 72-kDa metalloproteinase index.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; De Nictolis M; Romanini C; Biagini G
Gynecol Oncol; 1996 Apr; 61(1):83-9. PubMed ID: 8626123
[TBL] [Abstract][Full Text] [Related]
8. Ki67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance.
Garzetti GG; Ciavattini A; Goteri G; De Nictolis M; Stramazzotti D; Lucarini G; Biagini G
Gynecol Oncol; 1995 Feb; 56(2):169-74. PubMed ID: 7896180
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors.
Huang LW; Garrett AP; Bell DA; Welch WR; Berkowitz RS; Mok SC
Gynecol Oncol; 2000 Jun; 77(3):369-76. PubMed ID: 10831344
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
Gershenson DM; Deavers M; Diaz S; Tortolero-Luna G; Miller BE; Bast RC; Mills GB; Silva EG
Clin Cancer Res; 1999 Dec; 5(12):4053-8. PubMed ID: 10632339
[TBL] [Abstract][Full Text] [Related]
12. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters.
Lin CK; Chao TK; Yu CP; Yu MH; Jin JS
APMIS; 2009 Mar; 117(3):162-75. PubMed ID: 19245589
[TBL] [Abstract][Full Text] [Related]
13. [Assessment of prognostic factors in common ovarian tumors of varying malignancy].
Demeter A; Várkonyi T; Csapó Z; Szánthó A; Oláh J; Papp Z
Magy Onkol; 2004; 48(3):259-65. PubMed ID: 15520877
[TBL] [Abstract][Full Text] [Related]
14. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
Zhao XD; Zhang Q; Zhang Y
Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
[TBL] [Abstract][Full Text] [Related]
15. DNA fragmentation factor (DFF45): expression and prognostic value in serous ovarian cancer.
Brustmann H
Pathol Res Pract; 2006; 202(10):713-20. PubMed ID: 16962250
[TBL] [Abstract][Full Text] [Related]
16. High MMP-1 mRNA expression is a risk factor for disease-free and overall survivals in patients with invasive breast carcinoma.
Cheng S; Tada M; Hida Y; Asano T; Kuramae T; Takemoto N; Hamada J; Miyamoto M; Hirano S; Kondo S; Moriuchi T
J Surg Res; 2008 May; 146(1):104-9. PubMed ID: 17663001
[TBL] [Abstract][Full Text] [Related]
17. Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy.
Unsal D; Akyurek N; Uner A; Erpolat OP; Han U; Akmansu M; Mentes BB; Dursun A
Am J Clin Oncol; 2008 Feb; 31(1):55-63. PubMed ID: 18376229
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor expression as a prognostic index in serous ovarian cystoadenocarcinomas: relationship with MIB1 immunostaining.
Garzetti GG; Ciavattini A; Lucarini G; Pugnaloni A; De Nictolis M; Amati S; Romanini C; Biagini G
Gynecol Oncol; 1999 Jun; 73(3):396-401. PubMed ID: 10366466
[TBL] [Abstract][Full Text] [Related]
19. Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma.
Scheil-Bertram S; Tylus-Schaaf P; du Bois A; Harter P; Oppitz M; Ewald-Riegler N; Fisseler-Eckhoff A
Gynecol Oncol; 2010 Nov; 119(2):325-31. PubMed ID: 20728204
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]